Where AIDS Came From
Paul Sharp
Inst of Genetics, Univ of Nottingham, Queen's Med Ctr, UK

AIDS Restriction Genes: Discovery, Assessment and Implications
Stephen O'Brien
Lab of Genomic Diversity, NCI, Frederick, MD, US

Lack of Neutralizing Antibody Response to HIV-1 Predisposes to Superinfection
Davey Smith
Univ of California, San Diego, US

Broad Neutralization of HIV-1 Variants in Couples without Evidence of Systemic Superinfection Despite Exposure
Robert Grant
David Gladstone Insts, San Francisco, CA, US

Non-Neutralizing Antibody that Prevents SIV Infection in Neonatal Rhesus Macaques Potently Inhibits SIV in the Presence of Rhesus Macaque Effector Cells
Donald Forthal
Univ of California, Irvine Sch of Med, US

Simian Immunodeficiency Virus Engrafted with HIV-1-Specific Epitopes: Replication, Neutralization and Survey of HIV-1-Positive Plasma
Welkin Johnson
New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US

Defining and Measuring HIV-1 Escape from CTL: Epitope-Dependent Avidity Thresholds
Otto Yang
Univ of California, Los Angeles, US

Localized Populations of CD8- SIV-Specific T Cells in Lymphoid Follicles and Vaginal Epithelium
Pamela Skinner
Univ of Minnesota, St Paul, US

Maintenance of HIV-Specific CD4+ T-Cell Help Distinguishes HIV-2 from HIV-1 Infection
Melody Duvall
MRC Human Immunology Unit, Weatherall Inst of Molecular Med, Oxford, UK

Research Overview -- Immune Control of HIV Infection: Predictability in the Midst of Chaos
Bruce Walker
Partners AIDS Res Ctr, Harvard Med Sch, Boston, MA, US

High Cerebrospinal Fluid Neurofilament Protein Levels in AIDS Dementia Complex
Magnus Gisslén
Sahlgrenska Akademy at Göteborg Univ, Sweden

Leptin and Neuropsychological Performance: A New Biomarker for Cognitive Function?
Jeannie Huang
Univ of California, San Diego, US

Better Antiretroviral Penetration into the Central Nervous System Is Associated with Lower CSF Viral Load
Scott Letendre
Univ of California, San Diego, US

Discordance of Genotypic Resistance between CSF and Plasma Virus in a Multicenter Observational Cohort
Joseph Wong
VA Med Ctr San Francisco, CA US

The HIV Env N283 Genetic Variant Is Associated with Brain Infection and Dementia
Rebecca Dunfee
Dana-Farber Cancer Inst, Boston, MA, US and Harvard Med Sch, Boston, MA, US

Longitudinal Analysis of env Population Dynamics in Blood and Cerebrospinal Fluid of SIVsm-Infected Macaques
Patrick Harrington
Univ of North Carolina Sch of Med, Chapel Hill, US

Hemochromatosis Gene Polymorphisms and Peripheral Neuropathy during Antiretroviral Therapy: Analysis NWCS 238 of ACTG Study 384
Asha R Kallianpur
Vanderbilt Univ Sch of Med, Nashville, TN, US

Controlled Study of High-Concentration Capsaicin Patch for Painful HIV-Associated Distal Sensory Polyneuropathy
David Simpson
Mount Sinai Med Ctr, New York, NY, US

Research Overview: Update on Sensory Neuropathies
Justin McArthur
Johns Hopkins Univ Sch of Med, Baltimore, MD, US

Predictors of HIV Disease Progression in Patients Who Stop Antiretroviral Therapy with CD4 Cell Counts > 350 cells/mm3 (ACTG 5170)
Daniel Skiest
Baystate Med Ctr, Springfield, MA, US

CD4-Guided Scheduled Treatments Interruptions Compared to Continuous Therapy: Results of the Staccato Trial
Jintanat Ananworanich
HIV-NAT, Bangkok, Thailand

ISS PART: Final Results of a Randomized, Controlled Trial of Structured Treatment Interruptions versus Continuous HAART in Chronic HIV-Infected Subjects with Persistent Suppression of Viral Replication
Lucia Palmisano
Inst Superiore di Sanità, Rome, Italy

Structured Treatment Interruptions in HIV-Infected Patients with High CD4 Cell Counts and Virologic Suppression: Results of a Prospective, Randomized, Open-Label Trial (Window - ANRS 106)
Bruno Marchou
Hosp Purpan, Toulouse, France

Late Breaker - The CD4-guided Strategy Arm Stopped in a Randomized Structured Treatment Interruption (STI) Trial in West-African Adults: ANRS 1269 Trivacan Trial
Christine Danel
CHU de Treichville, Abidjan, Côte d'Ivoire

Late Breaker - Episodic CD4-Guided Use of Antiretroviral Therapy is Inferior to Continuous Therapy: Results of the SMART Study.
Wafaa El-Sadr and James Neaton
for the SMART Study Investigators

Late Breaker - Efficacy and Safety of Atazanavir-Based Therapy in Antiretroviral Naive HIV-1 Infected Subjects, Both With and Without Ritonavir: 48-Week Results from AI424-089
Niel Malan
Triple M Res, Port Elizabeth, South Africa

Late Breaker - A Prospective, Open-Label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone As Maintenance Antiretroviral Therapy After Sustained Virologic Suppression (ACTG 5201)
Susan Swindells
Univ of Nebraska Med Ctr, Omaha, US

Late Breaker - Safety of Nevirapine Compared to Abacavir on a Background of Zidovudine/Lamivudine as First-line Antiretroviral Therapy: a Randomised Double-Blind Trial
Paula Munderi
MRC/UVRI Uganda Res Unit on AIDS, Entebbe

Viral Decay Rates in Men and Women Receiving Triple-Nucleoside or Efavirenz -Containing Antiretroviral Therapy: Viral Dynamics Substudy of ACTG A5095
Kathleen Squires
Thomas Jefferson Univ, Philadelphia, PA

Utility of the Early Viral Response to Individually-Adjust the Duration of Treatment for Chronic Hepatitis C, Genotype 2 or 3, in HIV-Coinfected Patients
Manel Crespo
Vall d'Hebron's Hosp, Barcelona, Spain

Serum IP-10 Level Is Associated with Distinct Early Viral Dynamics in HCV and HCV-HIV Infected Subjects Treated with IFN-a
Benigno Rodriguez
Case Western Reserve Univ Ctr for AIDS Res

Effects of Cytokine Gene Polymorphisms on Treatment of Acute Hepatitis C Infection in HIV-Infected Patients
Jacob Nattermann
Dept of Internal Med I, Univ of Bonn, Germany

Virus-Specific T-Cell Responses and Loss of Spontaneous Control of HCV in HIV+ Individuals
Arthur Kim
Harvard Med Sch, Massachusetts Gen Hosp, Boston, US

Enhanced Replication of GB Virus C in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy
Per Björkman
Malmo Univ Hosp, Sweden and 2Lund Univ Hosp, Sweden

Evidence for Sexual Transmission of HCV in Recent Epidemic in HIV-Infected Men in the UK
Mark Danta
Royal Free and Univ Coll Med Sch, London, UK

Rise in HCV Incidence in HIV-infected Men Who Have Sex with Men in Amsterdam: Sexual Transmission of Difficult to Treat HCV Genotypes 1 and 4
Thijs van de Laar
Amsterdam HCV Study Group, The Netherlands

Systemic Overview of HAART-Associated Liver Enzyme Elevations (LEE) in Patients Infected with HIV and Coinfected with HCV
Yves Benhamou
Hosp Pitie Salpetriere, Paris, France

Implications of Early Events in HIV Infection for Treatment: Back to the Future?
Jeff Lifson
NCI, SAIC, Frederick, MD, US

Sex, Drugs and ... Outcome on Therapy
Monica Gandhi
Univ of California, San Francisco, US

Limiting the Limitations of Antiretrovirals
Andrew Carr
St Vincent's Hosp, Sydney, Australia

New Agents and Treatment Paradigms: Navigating through the Drug Development Mine Field
Michael Saag
Univ of Alabama at Birmingham, US

In Vitro Affinity Maturation of the HIV-1 Broadly Neutralizing Anti-gp41 Antibody Z13
Michael Zwick
The Scripps Res Inst, La Jolla, CA, US

Potential Difficulties in Eliciting Antibodies to the Membrane Proximal Region of HIV-1
Barton Haynes
Human Vaccine Inst, Duke Univ, Durham, NC, US

The Membrane Proximal External Region of HIV-1 on Different Viral Scaffolds: Detection of Epitope-specific Neutralizing Antibodies
George Shaw
Univ of Alabama at Birmingham and Howard Hughes Med Inst, US

Lessons from the Use of Membrane Proximal External Region Antibodies in vivo
Alexandra Trkola
Univ Hosp Zurich, Switzerland